scholarly journals Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

2017 ◽  
Vol 15 (7) ◽  
pp. 926-957 ◽  
Author(s):  
Margaret R. O'Donnell ◽  
Martin S. Tallman ◽  
Camille N. Abboud ◽  
Jessica K. Altman ◽  
Frederick R. Appelbaum ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Acute Myeloid

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (4) ◽  
pp. 520 ◽  
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
Innovative Strategies ◽  
Recent Version ◽  
Acute Myeloid

The incidence of leukemia, along with its precursor, myelodysplasia, appears to be rising, particularly in the population over age 60. Recently an expanded panel of clinicians from the NCCN member institutions joined to update guidelines for the treatment of acute myeloid leukemia. Although there are some areas in which clinical trials have led to significant improvements in treatment, for the most part, recent trials have only served to highlight the continued need for innovative strategies to overcome this disease. These guidelines focus on outlining reasonable treatment options based on the information available. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

2019 ◽  
Vol 17 (6) ◽  
pp. 721-749 ◽  
Author(s):  
Martin S. Tallman ◽  
Eunice S. Wang ◽  
Jessica K. Altman ◽  
Frederick R. Appelbaum ◽  
Vijaya Raj Bhatt ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
The United States ◽  
Nccn Guidelines ◽  
Younger Age ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark

2021 ◽  
pp. JCO.20.03142
Author(s):  
Selina M. Luger
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Myeloid Leukemia ◽  
Relevant Literature ◽  
Consolidation Therapy ◽  
Clinical Context ◽  
Case Presentation ◽  
Management Approaches ◽  
Grand Rounds ◽  
Acute Myeloid

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology

2006 ◽  
Vol 4 (1) ◽  
pp. 16 ◽  
Author(s):  
_ _
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Young Adulthood ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Innovative Strategies ◽  
The Past ◽  
Recent Version ◽  
Acute Myeloid

Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice

2018 ◽  
Vol 9 (5) ◽  
pp. 109-121 ◽  
Author(s):  
Christin B. DeStefano ◽  
Christopher S. Hourigan
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Drug Administration ◽  
Myeloid Leukemia ◽  
Initial Therapy ◽  
Gemtuzumab Ozogamicin ◽  
The Past ◽  
Molecular Etiology ◽  
Acute Myeloid

While the past decade has seen a revolution in understanding of the genetic and molecular etiology of the disease, in clinical practice, initial therapy for acute myeloid leukemia (AML) patients has been a relatively straightforward choice between intensive combination cytotoxic induction therapy as used for decades or less-intensive hypomethylating therapy. The year 2017, however, witnessed US Food and Drug Administration approvals of midostaurin, enasidenib, gemtuzumab ozogamicin and CPX-351 for AML patients, with many other promising agents currently in clinical trials. This review discusses these options, highlights unanswered questions regarding optimal combinations and proposes some suggested approaches for the personalization of initial therapy for AML patients.

Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

2012 ◽  
Vol 96 (3) ◽  
pp. 342-349 ◽  
Author(s):  
Takuya Matsunaga ◽  
Kiyoshi Yamashita ◽  
Yoko Kubuki ◽  
Takanori Toyama ◽  
Osamu Imataki ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Clinical Practice ◽  
Myeloid Leukemia ◽  
Population Based ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document